Outpatient Continuous Intravenous Interleukin‐2 or Subcutaneous, Polyethylene Glycol‐Modified Interleukin‐2 in Human Immunodeficiency Virus‐Infected Patients: A Randomized, Controlled, Multicenter Study

Open Access
Publisher Website
Google Scholar
Abstract
The safety and activity of outpatient-based continuous intravenous interleukin-2 (CIV IL-2) or a slow-release, polyethylene glycol (PEG)—modified IL-